From Bio프롬바이오
377220 · KOSDAQ · ₩377220 · 프롬바이오
₩1,909▼ ₩20 (1.04%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 63.0% | 57.6% | 55.3% | 68.9% | 69.8% | 75.6% |
| Operating margin | −22.7% | −25.8% | −36.1% | −23.1% | 0.9% | 8.5% |
| Net margin | −28.1% | −31.1% | −37.6% | −16.6% | 3.3% | 8.4% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −0.7% | +7.4% | +0.7% | −32.8% | −26.5% | — |
| Operating income growth | +12.5% | +23.4% | −57.4% | −1,819.1% | −92.1% | — |
| Net income growth | +10.3% | +11.2% | −128.3% | −441.8% | −71.3% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −78.6% | −57.4% | −39.9% | −13.5% | 3.8% | 13.4% |
| Return on assets | −31.4% | −31.7% | −29.4% | −12.1% | 1.4% | 11.7% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 186.8% | 149.6% | 65.3% | 29.5% | 7.8% | 14.2% |
| Net debt to equity | 4.9% | 14.2% | 3.1% | 15.9% | — | — |
| Current ratio | 40.2% | 48.9% | 106.7% | 171.9% | 833.3% | 615.8% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: From Bio / 프롬바이오 / 377220 / KRX:377220
Source: KRX statistical information